JPRN-UMIN000002716
Completed
Phase 2
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation - A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer with EGFR Mutation
Central Japan Lung Study Group (CJLSG)0 sites29 target enrollmentNovember 6, 2009
Conditionson-small cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- on-small cell lung cancer
- Sponsor
- Central Japan Lung Study Group (CJLSG)
- Enrollment
- 29
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Active infection or other serious disease condition (poorly controlled diabetes mellitus,cardiac disease, Unstable angina, Cardiac infarction, Psychological illness, etc.). 2\) Pulmonary disorder(idiopathic pulmonary fibrosis,interstitial lung disease, pneumoconiosis, active radiation pneumonia, etc.). 3\) Massive pleural effusion, pericardial effusion, ascites, and superior vena cava syndrome. 4\) Symptomatic brain metastasis. 5\) Severe drug allergy. 6\) Previous radiotherapy to primary lung cancer. 7\) Patients who have previously treated three or more chemotherapy. 8\) Patients who had a relapse after surgery. 9\) With active double cancer. 10\) Pregnancy or lactation. 11\) Severe disorder of the eye. 12\) Patients whose participation in the trial is judged to be inappropriate by the attending doctor.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54
Recruiting
Phase 2
A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer PatientsObjective of the study is to investigate efficacy and safety of Erlotinib for previously treated non-small cell lung cancer patients.JPRN-UMIN000004680Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine27
Completed
Phase 2
Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild typeadvanced or recurrent non-small-cell lung cancerJPRN-UMIN000008398Gunma Uninersity Hospital30
Completed
Phase 2
Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitison-small cell lung cancerJPRN-UMIN000007020ung Oncology Group in Kyushu, Japan (LOGIK)32
Completed
Phase 2
Phase II study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR(NEJ006/TCOG0903)Pre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000002795orth East Japan Study Group /The Tokyo Cooperative Oncology Group43